NCT00758446View on ClinicalTrials.gov

Efficacy and Safety Study of BLX-028914 in Subjects With Allergic Rhinitis

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

December 31, 2008

Study Completion Date

January 31, 2009

Conditions
Allergic Rhinitis
Interventions
DRUG

BLX-028914

50 mg capsules, p.o, daily, 14 days

DRUG

BLX-028914

15 mg capsules, p.o, daily, 14 days

DRUG

placebo

capsules, p.o, daily, 14 days

Trial Locations (1)

221 85

Department of otorhinolaryngology, Lund

Sponsors

Collaborators (1)

Orexo AB
All Listed Sponsors
collaborator

Orexo AB

INDUSTRY

lead

Dart NeuroScience, LLC

INDUSTRY

NCT00758446 - Efficacy and Safety Study of BLX-028914 in Subjects With Allergic Rhinitis | Biotech Hunter | Biotech Hunter